| Molecular Therapy Nucleic Acids
| [0016]
|
| Journal of Cell Science
| [0062]
|
| Int J Exp Pathol
| [0062]
|
| Proc Natl Acad Sci USA
| [0070]
|
| Muscle Nerve
| [0074]
[0211]
|
| PLoS Curr.
| [0074]
[0075]
|
| J Gen Med
| [0095]
|
| Sci Tranl Med
| [0135]
|
| Trends Cell Bio.
| [0136]
|
| Delivery Strategies for Antisense Oligonucleotide Therapeutics
| [0136]
|
| Cell Transplant
| [0141]
|
| Prog Neuropsychopharmacol Biol Psychiatry
| [0141]
|
| Chem. Rev.
| [0142]
|
| Chem. Pharm. Bull.
| [0142]
|
| Science
| [0142]
|
| Biochim. Biophys. Acta
| [0142]
|
| J. Biol. Chem.
| [0142]
|
| Pharmaceutical Salts
| [0144]
|
| Drug Development and Industrial Pharmacy
| [0177]
|
| REV
| [0177]
|
| J Pharm Sci
| [0177]
|
| Plant Cell Tiss. Org. Cult.
| [0186]
|
| Agnew. Chem. Int. Ed. Engl.
| [0186]
|
| New RRC, Liposomes: A practical approach
| [0193]
|
| Lasic DD, Liposomes from physics to applications
| [0193]
|
| Science
| [0200]
|
| Cancer Research
| [0200]
|
| Cell
| [0200]
|
| Science
| [0200]
|
| Am. J. Med. Sci.
| [0200]
|
| Science
| [0200]
|
| Am. J. Resp. Cell Molec. Biol.
| [0200]
|
| Proc. Natl. Acad. Sci. (USA)
| [0200]
|
| J. Biol. Chem.
| [0200]
|
| Science
| [0200]
|
| Am. J. Med. Sci.
| [0200]
|
| Clinical Research
| [0200]
|
| Science
| [0200]
|
| Population frequencies of inherited neuromuscular diseases - a world survey
| [0225]
|
| Evidence-based path to newborn screening for Duchenne muscular dystrophy
| [0225]
|
| Profiles of neuromuscular diseases. Duchenne muscular dystrophy
| [0225]
|
| Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
| [0225]
|
| Quality of life, physical disability and respiratory impairment in Duchenne muscular dystrophy
| [0225]
|
| Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy
| [0225]
|
| Glucocorticoid corticosteroids for Duchenne muscular dystrophy
| [0225]
|
| Local dystrophin restoration with antisense oligonucleotide PRO051
| [0225]
|
| Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
| [0225]
|
| Systemic administration of PRO051 in Duchenne's muscular dystrophy
| [0225]
|
| Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
| [0225]
|
| Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations
| [0225]
|
| Dystrophin and mutations: one gene, several proteins, multiple phenotypes
| [0225]
|
| The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history
| [0225]
|
| Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle
| [0225]
|
| Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy
| [0225]
|
| Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy
| [0225]
|
| Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression
| [0225]
|
| The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy
| [0225]
|
| Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study
| [0225]
|
| The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations
| [0225]
|
| Therapeutics in Duchenne muscular dystrophy
| [0225]
|
| Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy
| [0225]
|
| X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes
| [0225]
|
| The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology
| [0225]
|
| Clinical investigation in Duchenne dystrophy: 2. Determination of the ''power'' of therapeutic trials based on the natural history
| [0225]
|
| Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy
| [0225]
|
| Restoring dystrophin expression in Duchenne muscular dystrophy muscle: Progress in exon skipping and stop codon read through
| [0225]
|
| Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up
| [0225]
|
| Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse
| [0225]
|
| Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs
| [0225]
|
| Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense
| [0225]
|